A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

Asthma Clinical Trial

Official title:

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00590720
• Other study ID #: MI-CP143
• Status: Terminated
• Phase: Phase 2
• First received: December 26, 2007
• Last updated: February 4, 2014
• Start date: March 2008
• Est. completion date: October 2009

Study information

• Verified date: February 2014
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Description:

The primary objective of this study is to evaluate the safety and tolerability of multiple fixed escalating SC doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: October 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

Patients must meet all of the following criteria:

• Male or female adults, age 18 through 50 years at the time of screening;

• Weight 50-100 kg and body mass index = 35;

• Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;

• Documented clinical history of asthma and receiving stable treatment for = 1 month prior to Study Day 0;

• Airway hyperresponsiveness (AHR) on methacholine inhalation challenge testing at screening (or a documented history within the past 6 months), with provoking concentration of methacholine to cause a 20% fall in FEV1(subscript) (PC20) = 8 mg/mL (Crapo, 2000);

• Exercise-induced bronchoconstriction (EIB) with a decrease in FEV1 (subscript) of = 15% from pre-exercise challenge testing level at screening;

• Able to provide spirometry readings that meet American Thoracic Society (ATS) and European Respiratory Society (ERS) standards (Miller, 2005);

• Women of childbearing potential, unless surgically sterile or at least 1 year post-menopausal, must use two effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom, spermicide, diaphragm, cervical cap, abstinence, contraceptive foam, or use of a condom by the sexual partner or sterile sexual partner) from screening through Study Day 0, and must agree to continue using such precautions through Study Day 150. Cessation of birth control after this point should be discussed with a responsible physician. Men, unless surgically sterile, must likewise use an effective method of birth control (condom with spermicide) and must agree to continue using such precautions from screening through Study Day 150;

• Able to complete the study period, including follow-up period, of up to approximately 150 days; and

• Willing to forego other forms of experimental treatment and study procedures during the study and for 30 days after the follow-up period is completed.

Exclusion Criteria:

Patients must have none of the following criteria:

• Receipt of MEDI-528 in any previous clinical study;

• History of allergy or reaction to any component of the study drug formulation;

• Lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic fibrosis);

• Forced expiratory volume in 1 second (FEV1-subscript) < 70% of predicted values at screening;

• Use of systemic immunosuppressive drugs including systemic corticosteroids, ICS with doses > 800 µg/day budesonide (or another ICS of equivalent dose), long-acting ß2 agonists, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists, theophylline, or omalizumab from screening through Study Day 150;

• Current use of any ß-adrenergic antagonist (eg, propranolol);

• Any disease or illness, other than asthma, that is likely to require the use of systemic corticosteroids during the study period;

• Acute illnesses or evidence of significant active infection, such as fever = 38.0°C (100.5°F) from screening through Study Day 0;

• Current allergy vaccination therapy (desensitization immunotherapy);

• Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to screening;

• Pregnancy (women of child bearing potential, unless surgically sterile or at least 1 year postmenopausal, must have a negative serum and urine pregnancy test at screening before methacholine inhalation challenge testing and a negative urine pregnancy test prior to study drug administration on Study Day 0);

• Breastfeeding or lactating woman;

• Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active infection with hepatitis A; must have negative HIV-1, HIV-2, hepatitis A, B, and C tests at screening;

• History of cancer other than basal cell carcinoma of the skin or cervical carcinoma-in-situ treated with apparent success with curative therapy more than 1 year prior to Study Day 0;

• History of primary immunodeficiency

• History of pancreatitis or currently active gastroduodenal ulcer;

• Current use of tobacco products or a history of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of = 10 pack-years;

• History of life-long urinary retention;

• History of anaphylaxis (defined as immediate life-threatening event requiring medical invention);

• Elective surgery planned from screening through Study Day 150;

• Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at screening;

• History of any disease, evidence of any current disease (other than asthma), any finding upon physical examination, or any laboratory abnormality, that, in the opinion of the investigator or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study; or

• Any employee of the research site who is involved with the conduct of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma

Intervention

Biological:
• MEDI528 50 mg
MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks

Other:
• PLACEBO
Placebo administered as a subcutaneous injection twice weekly for 4 weeks

Locations

Country	Name	City	State
Canada	Calgary COPD & Asthma Program	Calgary	Alberta
Canada	Centre de Recherche Appliquee en Allergie de Quebec	Quebec City	Quebec
Canada	UHN- Toronto Western Hospital	Toronto	Ontario
United States	Bernstein Clinical Research Center	Cincinnati	Ohio
United States	National Jewish Medical and Research Center	Denver	Colorado
United States	Northeast Medical Research Associates, Inc	No. Dartmouth	Massachusetts
United States	Sneeze,Wheeze & Itch Associates, LLC	Normal	Illinois
United States	Creighton University	Omaha	Nebraska
United States	Institute of Healthcare Assessment, Inc	San Diego	California
United States	The Clinical Research Center, LLC	St. Louis	Missouri
United States	Univ. of South Florida, Asthma, Allergy & Immunology Clinical Research Unit	Tampa	Florida
United States	Waterbury Pulmonary Associates	Waterbury	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events	Number of participants experiencing adverse events (includes both adverse events and serious adverse events)	Days 0 - 150	Yes
Primary	Incidence of Serious Adverse Events	Number of participants experiencing serious adverse events	Days 0 - 150	Yes
Secondary	Incidence of Anti-drug Antibodies (ADA) to MEDI-528	Number of participants with ADA to MEDI-528	Days 0, 28, 56, 119, and 150	Yes
Secondary	Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 measured before and after exercising on Day 28.	Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 56.	Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the maximum change in FEV1 before and after exercise on Day 150.	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 28.	Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 56.	Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)	The clinical activity of MEDI-528 on exercise-induced bronchoconstriction was measured by exercise challenge testing expressed as the percent maximum change in FEV1 before and after exercise on Day 150.	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)	AUC of FEV1 at Day 28	Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)	AUC of FEV1 at Day 56	Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)	AUC of FEV1 at Day 150	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)	Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after 30 minues of exercise on Day 28	Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)	Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 56	Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)	Time to return in minutes to 90 percent of baseline FEV1 (prior to exercise) after exercise on Day 150	Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)	No
Secondary	Mean Trough Concentration (Cmin)	Cmin of MEDI-528	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	No
Secondary	Mean Trough Concentration at Last Measurable Time Point (Cmin_last)	Cmin_last of MEDI-528	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	No
Secondary	Half-life (T1/2)	T1/2 of MEDI-528	Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150	No
Secondary	Accumulation Index	Ratio of trough concentrations after first (Day 0) and last (Day 24) dose of MEDI-528	Days 0 and 24	No